Sort
40,608 grants matching “prostate cancer”
Validating and Extending the PROMIS Sexual Function Measure for Clinical Research
$506,363Kevin P Weinfurt · Duke University · U01 · FY2010 · AR
Unravel a novel metabolic pathway orchestrating prostate cancer progression and therapeutic resistance
$506,358Hui-Kuan Lin · Duke University · R01 · FY2023 · CA
Postdoctoral Training Program in Cancer Epidemiology
$506,337Susan M Gapstur · Northwestern University At Chicago · R25 · FY2006 · CA
Radiation, Hormones & Antisense Prostate Cancer Therapy
$506,334Alan Pollack · Fox Chase Cancer Center · R01 · FY2007 · CA
Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis
$506,326Haojie Huang · Mayo Clinic Rochester · R01 · FY2022 · CA
HIFU-enhanced tumor vaccines
$506,243Chandan Guha · Albert Einstein College Of Medicine · R01 · FY2008 · EB
Exploiting ferroportin for cancer imaging and therapy
$506,089Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
Specialized Histopathology
$506,028Jon C Aster · Dana-Farber Cancer Inst · P30 · FY2015 · CA
Mcl-1 in apoptosis and signal transduction: a structure/function approach
$505,956Maurizio Pellecchia · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2014 · CA
Human aldo-keto reductases and nuclear receptor action
$505,848Trevor M. Penning · University Of Pennsylvania · R01 · FY2009 · CA
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer
$505,760David W Goodrich · Roswell Park Cancer Institute Corp · R01 · FY2018 · CA
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer
$505,760David W Goodrich · Roswell Park Cancer Institute Corp · R01 · FY2016 · CA
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer
$505,760David W Goodrich · Roswell Park Cancer Institute Corp · R01 · FY2020 · CA
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer
$505,760David W Goodrich · Roswell Park Cancer Institute Corp · R01 · FY2017 · CA
DRUG DELIVERY CPPs
$505,759Rudolph Juliano · Univ Of North Carolina Chapel Hill · P01 · FY2007 · GM
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival
$505,733Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2015 · CA
PI-3 Kinase Therapy in Mouse Tumor Models
$505,691Columbia University Health Sciences · R01 · FY2002 · CA
Neurocognitive Changes from Long-Term Androgen Deprivation Therapy in Prostate Cancer Patients
$505,673Herta Huey-An Chao · Yale University · R01 · FY2019 · CA
Exosome separation and digital resolution detection of blood-based nucleic acid biomarkers for noninvasive therapeutic diagnostics in cancer
$505,588Brian T. Cunningham · University Of Illinois At Urbana-Champaign · R01 · FY2021 · EB
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy
$505,583Alan Keith Meeker · Johns Hopkins University · R01 · FY2024 · CA
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies
$505,524Nupam P Mahajan · Washington University · R01 · FY2020 · CA
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
$505,476Harvard University (Medical School) · R01 · FY2003 · EB
New Tools for Prostate Cancer Detection and Prognostication
$505,451Sanjiv S Gambhir · Stanford University · U01 · FY2013 · CA
Specialized Histopathology
$505,418Jon C Aster · Dana-Farber Cancer Inst · P30 · FY2016 · CA
TempO-Seq for Preserved Tissues in Toxicity Testing Phase II
$505,295Bruce E. Seligmann · Biospyder Technologies, Inc. · R44 · FY2018 · ES